The Congress Hub brings to you the latest updates from the “Education Symposium on Atopic Dermatitis” that was conducted on May 19^th 2023, as a part of the European Academy of Dermatology and Venereology’s (EADV) Spring Symposium series. The educational resource focuses on the disease burden, pathophysiology, and the effectiveness of Dupixent-  the first treatment approved in the European Union (EU) for severe atopic dermatitis (AD) in children between the ages of 6 months to 11 years who are candidates for systemic therapy.